Difference between revisions of "Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection"
(Created page with "Category:Article Category:Covid19 {| class="infobox" width=200px |class="publication"|'''Publication''' |- |Title || <ul>[https://onlinelibrary.wiley.com/doi/10.1002/j...") |
|||
| Line 25: | Line 25: | ||
== Major Issues == | == Major Issues == | ||
| − | No major issues identified. | + | No major issues identified at this time. |
== Minor Issues == | == Minor Issues == | ||
| − | No minor issues identified. | + | No minor issues identified at this time. |
== Impact == | == Impact == | ||
Latest revision as of 17:04, 22 July 2020
| Publication | |
| Title | |
| Authors |
|
| Journal | Journal of Medical Virology |
| Date | July 9, 2020 |
Retrospective analysis of patients with systemic lupus erythematosus, rheumatoid arthritis and other autoimmune disorders showed that patients receiving hydroxychloroquine had an odds ratio of COVID-19 of 0.51 (CI 0.37-0.70) compared to patients with autoimmune diseases who were receiving other therapeutics.
This analysis suggests a prophylactic effect of hydroxychloroquine against COVID-19.
Of note, hydroxychloroquine was not shown to be entirely protective against COVID-19 as 5.96% of patients receiving chronic treatment with hydroxychloroquine still became infected with novel-coronavirus compared to the 7.45% infection incidence in patients not receiving hydroxychloroquine.
Major Issues
No major issues identified at this time.
Minor Issues
No minor issues identified at this time.
Impact
This is another retrospective analysis that suggests a prophylactic effect of hydroxychloroquine against COVID-19.
Article Revisions
None at this time.